Loading…
Octreotide in the management of postoperative chylothorax
Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience wit...
Saved in:
Published in: | Pediatric cardiology 2005-08, Vol.26 (4), p.440-443 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3 |
---|---|
cites | cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3 |
container_end_page | 443 |
container_issue | 4 |
container_start_page | 440 |
container_title | Pediatric cardiology |
container_volume | 26 |
creator | Rosti, L De Battisti, F Butera, G Cirri, S Chessa, M Delogu, A Drago, M Giamberti, A Pomè, G Carminati, M Frigiola, A |
description | Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs. |
doi_str_mv | 10.1007/s00246-004-0820-4 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68918692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A152066810</galeid><sourcerecordid>A152066810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</originalsourceid><addsrcrecordid>eNptkdtKAzEQhoMoWg8P4I0sCN5FJ9k0h0sRTyB4o9chZmfbld1NTVKxb29KCyKUEALD92dm-Ag5Z3DNANRNAuBCUgBBQXOgYo9MmKg5ZUaxfTIBpjgFKeojcpzSJwBo0NNDcsRkrYQ0YkLMq88RQ-4arLqxynOsBje6GQ445iq01SKkHBYYXe6-sfLzVR_yPET3c0oOWtcnPNu-J-T94f7t7om-vD4-392-UC9AZKqx9DFetHzKjWuNdtoLBdgqKRUHXi7DMrzkdf3hjFNKKMd0rZtpo5nH-oRcbf5dxPC1xJTt0CWPfe9GDMtkpTZMS8MLeLkBZ65H241tyNH5NWxv2bR0kJpBoegOaoZjWbEPI7ZdKf_jr3fw5TQ4dH5ngG0CPoaUIrZ2EbvBxZVlYNfa7EabLdrsWpsVJXOx3XH5MWDzl9h6qn8BTiyPbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68918692</pqid></control><display><type>article</type><title>Octreotide in the management of postoperative chylothorax</title><source>Springer Nature</source><creator>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</creator><creatorcontrib>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</creatorcontrib><description>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</description><identifier>ISSN: 0172-0643</identifier><identifier>EISSN: 1432-1971</identifier><identifier>DOI: 10.1007/s00246-004-0820-4</identifier><identifier>PMID: 16374694</identifier><language>eng</language><publisher>United States: Springer</publisher><subject>Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Agents, Hormonal - therapeutic use ; Chest ; Child ; Child, Preschool ; Chylothorax ; Chylothorax - drug therapy ; Chylothorax - etiology ; Complications and side effects ; Diagnosis ; Drug therapy ; Female ; Follow-Up Studies ; Humans ; Infant ; Infusions, Intravenous ; Length of Stay ; Male ; Octreotide - administration & dosage ; Octreotide - therapeutic use ; Octreotide acetate ; Postoperative Complications ; Prospective Studies ; Surgery ; Thoracic Surgical Procedures - adverse effects ; Treatment Outcome</subject><ispartof>Pediatric cardiology, 2005-08, Vol.26 (4), p.440-443</ispartof><rights>COPYRIGHT 2005 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</citedby><cites>FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16374694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosti, L</creatorcontrib><creatorcontrib>De Battisti, F</creatorcontrib><creatorcontrib>Butera, G</creatorcontrib><creatorcontrib>Cirri, S</creatorcontrib><creatorcontrib>Chessa, M</creatorcontrib><creatorcontrib>Delogu, A</creatorcontrib><creatorcontrib>Drago, M</creatorcontrib><creatorcontrib>Giamberti, A</creatorcontrib><creatorcontrib>Pomè, G</creatorcontrib><creatorcontrib>Carminati, M</creatorcontrib><creatorcontrib>Frigiola, A</creatorcontrib><title>Octreotide in the management of postoperative chylothorax</title><title>Pediatric cardiology</title><addtitle>Pediatr Cardiol</addtitle><description>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</description><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Chest</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chylothorax</subject><subject>Chylothorax - drug therapy</subject><subject>Chylothorax - etiology</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infant</subject><subject>Infusions, Intravenous</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Octreotide - administration & dosage</subject><subject>Octreotide - therapeutic use</subject><subject>Octreotide acetate</subject><subject>Postoperative Complications</subject><subject>Prospective Studies</subject><subject>Surgery</subject><subject>Thoracic Surgical Procedures - adverse effects</subject><subject>Treatment Outcome</subject><issn>0172-0643</issn><issn>1432-1971</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNptkdtKAzEQhoMoWg8P4I0sCN5FJ9k0h0sRTyB4o9chZmfbld1NTVKxb29KCyKUEALD92dm-Ag5Z3DNANRNAuBCUgBBQXOgYo9MmKg5ZUaxfTIBpjgFKeojcpzSJwBo0NNDcsRkrYQ0YkLMq88RQ-4arLqxynOsBje6GQ445iq01SKkHBYYXe6-sfLzVR_yPET3c0oOWtcnPNu-J-T94f7t7om-vD4-392-UC9AZKqx9DFetHzKjWuNdtoLBdgqKRUHXi7DMrzkdf3hjFNKKMd0rZtpo5nH-oRcbf5dxPC1xJTt0CWPfe9GDMtkpTZMS8MLeLkBZ65H241tyNH5NWxv2bR0kJpBoegOaoZjWbEPI7ZdKf_jr3fw5TQ4dH5ngG0CPoaUIrZ2EbvBxZVlYNfa7EabLdrsWpsVJXOx3XH5MWDzl9h6qn8BTiyPbA</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Rosti, L</creator><creator>De Battisti, F</creator><creator>Butera, G</creator><creator>Cirri, S</creator><creator>Chessa, M</creator><creator>Delogu, A</creator><creator>Drago, M</creator><creator>Giamberti, A</creator><creator>Pomè, G</creator><creator>Carminati, M</creator><creator>Frigiola, A</creator><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>Octreotide in the management of postoperative chylothorax</title><author>Rosti, L ; De Battisti, F ; Butera, G ; Cirri, S ; Chessa, M ; Delogu, A ; Drago, M ; Giamberti, A ; Pomè, G ; Carminati, M ; Frigiola, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Chest</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chylothorax</topic><topic>Chylothorax - drug therapy</topic><topic>Chylothorax - etiology</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infant</topic><topic>Infusions, Intravenous</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Octreotide - administration & dosage</topic><topic>Octreotide - therapeutic use</topic><topic>Octreotide acetate</topic><topic>Postoperative Complications</topic><topic>Prospective Studies</topic><topic>Surgery</topic><topic>Thoracic Surgical Procedures - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosti, L</creatorcontrib><creatorcontrib>De Battisti, F</creatorcontrib><creatorcontrib>Butera, G</creatorcontrib><creatorcontrib>Cirri, S</creatorcontrib><creatorcontrib>Chessa, M</creatorcontrib><creatorcontrib>Delogu, A</creatorcontrib><creatorcontrib>Drago, M</creatorcontrib><creatorcontrib>Giamberti, A</creatorcontrib><creatorcontrib>Pomè, G</creatorcontrib><creatorcontrib>Carminati, M</creatorcontrib><creatorcontrib>Frigiola, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosti, L</au><au>De Battisti, F</au><au>Butera, G</au><au>Cirri, S</au><au>Chessa, M</au><au>Delogu, A</au><au>Drago, M</au><au>Giamberti, A</au><au>Pomè, G</au><au>Carminati, M</au><au>Frigiola, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Octreotide in the management of postoperative chylothorax</atitle><jtitle>Pediatric cardiology</jtitle><addtitle>Pediatr Cardiol</addtitle><date>2005-08</date><risdate>2005</risdate><volume>26</volume><issue>4</issue><spage>440</spage><epage>443</epage><pages>440-443</pages><issn>0172-0643</issn><eissn>1432-1971</eissn><abstract>Chylothorax (KT) may be a complication of thoracic surgery. Its management is not well established and may comprise dietary interventions and surgery. The effectiveness of somatostatin and its analogues has been reported, although their mechanism(s) of action is unclear. We report our experience with octreotide in a series of patients with postoperative chylothorax. Eight patients with KT were treated with a continuous intravenous infusion of octreotide (OCT) at a starting dose of 0.5 microg/kg/hr. They were compared with four additional patients with KT who were treated according to the conventional approach. After a mean of 3.3 +/- 1.9 days of treatment, fluid discharge diminished dramatically. In all patients, fluid losses stopped by postoperative day 10.5 +/- 2.9 and chest tubes could be removed after 12.8 +/- 4.1 days. Compared to a small group of historical controls, OCT reduced significantly the total fluid losses (141.1 +/- 89.3 vs 396.7 +/- 151.0 ml/kg; p = 0.003) and the postoperative length of stay (p = 0.05). No patients in the group treated with OCT required parenteral nutrition (compared to all four of the controls; p = 0.002) and/or thoracenteses (compared to two of four controls). In postoperative KT, OCT seems to be at least as effective as the conventional approach. Furthermore, OCT may reduce total fluid losses and postoperative length of stay. This may have a beneficial effect on the risk of complications and on hospital costs.</abstract><cop>United States</cop><pub>Springer</pub><pmid>16374694</pmid><doi>10.1007/s00246-004-0820-4</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0172-0643 |
ispartof | Pediatric cardiology, 2005-08, Vol.26 (4), p.440-443 |
issn | 0172-0643 1432-1971 |
language | eng |
recordid | cdi_proquest_miscellaneous_68918692 |
source | Springer Nature |
subjects | Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - therapeutic use Chest Child Child, Preschool Chylothorax Chylothorax - drug therapy Chylothorax - etiology Complications and side effects Diagnosis Drug therapy Female Follow-Up Studies Humans Infant Infusions, Intravenous Length of Stay Male Octreotide - administration & dosage Octreotide - therapeutic use Octreotide acetate Postoperative Complications Prospective Studies Surgery Thoracic Surgical Procedures - adverse effects Treatment Outcome |
title | Octreotide in the management of postoperative chylothorax |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Octreotide%20in%20the%20management%20of%20postoperative%20chylothorax&rft.jtitle=Pediatric%20cardiology&rft.au=Rosti,%20L&rft.date=2005-08&rft.volume=26&rft.issue=4&rft.spage=440&rft.epage=443&rft.pages=440-443&rft.issn=0172-0643&rft.eissn=1432-1971&rft_id=info:doi/10.1007/s00246-004-0820-4&rft_dat=%3Cgale_proqu%3EA152066810%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-8e6949c4f2529af98a8c470ef76672027201e8206233ba9a7747a1838d5d81ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68918692&rft_id=info:pmid/16374694&rft_galeid=A152066810&rfr_iscdi=true |